Tag Archives: Congress

Pharma's Influence on the Super Committee: Is Cash Really King?

By Ben Comer | Published: August 16, 2011
Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to Center for Responsive Politics data, and a MapLight analysis.
Posted in Strategy, healthcare, leadership | Also tagged , , , , , | 1 Comment

US Mid-Term Elections: What It Means for Pharma

By William Looney | Published: November 3, 2010
Daily News Nugget US Mid-Term Elections:  What it Means for Pharma Drink up, even if it’s  only old wine in new bottles… Yesterday’s mid-term congressional poll barely changes the stakes for pharma in its pursuit of its US legislative and regulatory agenda.    The key message coming out of the results is stalemate on the big issues like [...]
Posted in Op-Ed, Regulatory | Also tagged , , , , , , | 3 Comments

Health Reform Hazards: Steering Your Course Through the Rhetorical Shallows

By William Looney | Published: December 9, 2009
Image by Getty Images via Dayli Crafting consensus legislation on health reform depends heavily on all parties understanding precisely the terms of the debate. With the two House and Senate bills now topping out at more than 4,000 text pages, prospects for even a basic awareness of the implications of this reform for big pharma and [...]
Posted in FDA, News | Also tagged , , , , , , | Leave a comment

The Trouble with Transparency

By George Koroneos | Published: November 6, 2009
Guest blog by Jacky Law A couple of weeks ago I attended an industry awards dinner and had an interesting conversation with an eminent doctor who shall remain nameless. The doctor in question works in a highly specialized area and frequently talks about her research at conferences around the world. She always travels first-class and has [...]
Posted in Guest Blog, Strategy | Also tagged , , , , , , | Leave a comment

Wyeth v. Levine: Inside the Preemption Case

By Walter Armstrong | Published: November 10, 2008
Last week, the Supreme Court heard arguments in the long-awaited preemption case, Wyeth v. Levine. For the first time, the highest court in the land is weighing in on whether federal approval of a drug preempts tort claims against a drugmaker, such as an injured consumer might bring in a state court. A decision for [...]
Posted in Legal, Regulatory | Also tagged , , , , , | Leave a comment